Search
for
Sort by
Research 31–60 of 1000+
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Response to Ranpariya et al.’s “Direct-to-consumer teledermatology platforms may have inherent conflicts of interest.”
- Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Off-label prescriptions: patient safety first
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology
- Mercury rising
- Alopecia areata: current concepts
- Letter to the Editor: A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Healthcare System
- Coming full circle (almost): Low dose oral minoxidil for alopecia
- Impact of a health alert and its implementation on flutamide prescriptions for women: an interrupted time series analysis
- The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
- Pharmacological Treatment of Alopecia
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Unknown safety profile of ingredients in hair supplements: A call to action for improved patient safety
- Efficacy and Safety of Spironolactone in Acne Management
- Exploring novel management options for alopecia areata
- The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
- Biologics in the management of childhood atopic dermatitis
- Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
- Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review
- Reporting on Adverse Clinical Events
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)